Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 247

Results For "development"

3694 News Found

Moderna sues Pfizer, BioNTech for mRNA patent infringement
News | August 28, 2022

Moderna sues Pfizer, BioNTech for mRNA patent infringement

Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016


Syngene International forms a new subsidiary
News | August 28, 2022

Syngene International forms a new subsidiary

The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind


Syngene International to acquire stake in O2 Renewable Energy II
News | August 28, 2022

Syngene International to acquire stake in O2 Renewable Energy II

A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power


Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles
News | August 27, 2022

Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles

The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive


10th Merck Bioforum India 2022 on Sept. 6-8
News | August 26, 2022

10th Merck Bioforum India 2022 on Sept. 6-8

This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape


Pristyn Care witnesses industry highest adoption of EMR
Healthcare | August 26, 2022

Pristyn Care witnesses industry highest adoption of EMR

99% of Pristyn Doctors are using EMR facility on its doctor app


Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer
Drug Approval | August 26, 2022

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients


Lupin receives approval from US FDA for Formoterol Fumarate Inhalation Solution
Drug Approval | August 25, 2022

Lupin receives approval from US FDA for Formoterol Fumarate Inhalation Solution

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US


Celanese announces Grant Award to develop refillable drug delivery solution
News | August 24, 2022

Celanese announces Grant Award to develop refillable drug delivery solution

Celanese to conduct research, prototype development and characterization of a refillable contraceptive technology with award from the Bill & Melinda Gates Foundation